U.S. Markets open in 3 hrs 18 mins
  • S&P Futures

    4,236.50
    +0.25 (+0.01%)
     
  • Dow Futures

    33,871.00
    +36.00 (+0.11%)
     
  • Nasdaq Futures

    14,262.00
    +3.75 (+0.03%)
     
  • Russell 2000 Futures

    2,289.40
    -3.10 (-0.14%)
     
  • Crude Oil

    73.43
    +0.58 (+0.80%)
     
  • Gold

    1,782.80
    +5.40 (+0.30%)
     
  • Silver

    26.00
    +0.15 (+0.57%)
     
  • EUR/USD

    1.1940
    -0.0003 (-0.0239%)
     
  • 10-Yr Bond

    1.4720
    0.0000 (0.00%)
     
  • Vix

    16.45
    -1.44 (-8.05%)
     
  • GBP/USD

    1.3962
    +0.0015 (+0.1075%)
     
  • USD/JPY

    111.0680
    +0.4330 (+0.3914%)
     
  • BTC-USD

    33,968.78
    +2,319.52 (+7.33%)
     
  • CMC Crypto 200

    812.49
    +18.17 (+2.29%)
     
  • FTSE 100

    7,099.70
    +9.69 (+0.14%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Talaris Therapeutics Announces Closing of Initial Public Offering

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol “TALS.” All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission on May 6, 2021. This offering was made only by means of a written prospectus. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky.

Media Contact:

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783